Newsroom

Industry News

1 Jul

GenSpera Inc. – “Pricing vs Value of Cancer Drugs”

GenSpera Inc. (GNSZ) today published a new blog post on The Chairman’s Blog, written by the Company’s chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. In his...

Read more

1 Jul

Arch Therapeutics Announces Private Placement

$3.0 Million in Net Proceeds Expected Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company“), developer of the AC5 Surgical Hemostatic Device™ (“AC5™“), is pleased to announce that it raised $3,066,000 in equity financing in a private placement to 19 accredited investors (the “Investors“) on June 30, 2015 (the “Initial...

Read more

29 Jun

Enrollment in Relmada Therapeutics’ Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark

Company On Track to Report Top-Line Data in Second Half of 2015 Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028)...

Read more

29 Jun

The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML

– This is part of the existing $5 Million Therapy Acceleration Program partnership – – Accelerated payment based on recently reported positive induction response rate – Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that The Leukemia & Lymphoma Society® (LLS) is accelerating a portion of the final payment linked to the...

Read more

26 Jun

Bioline RX Ltd (BLRX) Up Again; Broadfin, Rima Senvest Love The Stock

Bioline RX Ltd  (NASDAQ:BLRX) shares are up another 17% today, bringing its cumualtive return to above 30% over the past week. JP Morgan initiated coverage and set a $5 price target earlier this week. “BioLine RX is advancing an arsenal of products in development with the hope of delivering...

Read more

25 Jun

Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer

Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it has entered into a non-exclusive clinical trial collaboration with Incyte Corporation (Nasdaq: INCY) to evaluate the combination of Immunovaccine’s novel T cell activating immunotherapy, DPX-Survivac, with Incyte’s investigational oral indoleamine...

Read more

25 Jun

Harvard Apparatus Regenerative Technology Appoints James McGorry as New Chief Executive Officer

-Mr. McGorry brings extensive management and commercialization experience in biologics, personalized medicine and medical device spaces- -HART plans to provide a corporate update on its second quarter financial call in August 2015- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a biotechnology company developing bioengineered organs for clinical use,...

Read more

24 Jun

Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia

CPX-351 demonstrates a 43.2% relative improvement in induction response rate Conference call today at 8:30am Eastern Time to discuss the results Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study...

Read more

Page 1 of 8012345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets